IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
- IN8bio unveils new preclinical data for its INB-300 non-signaling gamma-delta T cell CAR platform at the 2024 AACR Annual Meeting.
- The platform demonstrates the ability to target cancer cells while preserving healthy tissues, a critical advancement in CAR-T therapy.
- IN8bio's nsCAR technology leverages gamma-delta T cells to differentiate between tumor and healthy tissue, enhancing precision in cancer treatment.
- None.
Insights
The development of IN8bio's non-signaling gamma-delta T cell CAR-T platform, INB-300, represents a significant advancement in the field of cancer treatment. Gamma-delta T cells are a subset of T cells that possess innate-like properties, which enable them to recognize and eliminate cancerous cells without the requirement for major histocompatibility complex (MHC) molecules. This feature is particularly advantageous as it allows the targeting of a broader range of tumor antigens that are not restricted by MHC, which is a limitation of conventional T cell therapies.
The ability of INB-300 to discern between cancerous and healthy cells despite the presence of the same antigen on both is a potential game-changer. This could greatly reduce the incidence of 'on-target, off-tumor' toxicities, a common side effect of current CAR-T therapies where healthy cells are inadvertently attacked, leading to serious complications. By preserving healthy tissues, INB-300 could offer a safer treatment option and possibly extend its applicability to solid tumors, which have been challenging to treat with existing CAR-T therapies due to the difficulty in distinguishing between healthy and cancerous cells.
Moreover, targeting CD-33 and CD-123 antigens, which are expressed on myeloid malignancies, could address a significant unmet need in leukemia treatment. The preclinical success of INB-300 might translate into a competitive edge for IN8bio in the biopharmaceutical industry, potentially leading to partnerships, increased funding and a rise in stock valuation if clinical trials confirm the preclinical findings.
Current CAR-T cell therapies, although revolutionary, have been predominantly successful in treating certain hematological malignancies, such as B-cell lymphomas and leukemias. The challenge with solid tumors and some myeloid malignancies has been the lack of specificity, leading to significant damage to healthy tissues. The nsCAR platform's ability to mitigate this issue could revolutionize the treatment landscape for a wider array of cancers, including those considered 'undruggable'.
This advancement could lead to improved patient outcomes, as the selective targeting of cancer cells would likely result in fewer adverse effects and improved tolerability. This is particularly important for patients who are often debilitated by both the disease and the treatment side effects. If INB-300 progresses to clinical trials and demonstrates efficacy and safety in humans, it could become a cornerstone treatment, potentially improving survival rates and quality of life for cancer patients.
From a clinical perspective, the poster presentation at AACR is an opportunity for the oncology community to scrutinize the data and methodology behind INB-300. The feedback and discussions generated could guide further development and optimization of the therapy.
The preclinical success of the INB-300 platform could have substantial implications for IN8bio's market positioning. The global CAR-T therapy market is experiencing rapid growth and innovations that offer potential safety and efficacy improvements are likely to capture significant interest from investors, healthcare providers and patients alike.
As an emerging player in the field, IN8bio's focus on addressing the limitations of current CAR-T therapies could attract strategic partnerships or licensing deals, particularly with larger pharmaceutical companies seeking to diversify their oncology portfolios. The ability to target solid tumors effectively would open up a large segment of the cancer treatment market, currently underserved by existing CAR-T therapies.
From a financial standpoint, positive preclinical results typically lead to a positive market reaction, as they increase the likelihood of successful clinical trials and eventual FDA approval. Investors will be closely watching the progress of INB-300 through clinical development, as each milestone achieved has the potential to influence IN8bio's stock performance.
- New preclinical data demonstrating proof-of-concept for the non-signaling gamma-delta T cell CAR (nsCAR) platform candidate targeting CD-33 and CD-123 will be presented.
- The platform has demonstrated the ability to target cancer cells while sparing healthy tissue when both express the CAR-targeted antigens, which could be used for previously “undruggable” solid and liquid tumor targets.
NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced the presentation of new preclinical data for its non-signaling gamma-delta T cell based Chimeric Antigen Receptor T cell (CAR-T) platform, INB-300. The data will be presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, California.
The current generation of CAR-T technology eliminates the target antigen regardless of whether it is expressed on tumor or healthy tissue. IN8bio's nsCAR platform, INB-300, uses the CAR to traffic and bind to cells expressing the target and leverages the natural innate immune recognition abilities of gamma-delta T cells to distinguish between tumor and healthy tissue. This allows the cells to selectively eliminate cancer cells while leaving healthy cells intact, even when both express the CAR-target.
“We're excited to share this new data from our nsCAR platform, INB-300, which enables next-generation precision CAR-T therapy by selectively targeting leukemia cells while preserving healthy tissues,” said Lawrence Lamb, Ph.D., co-founder and Chief Scientific Officer, IN8bio. “We are using gamma-delta T cells to treat a wide variety of cancers, including myeloid malignancies and solid tumors, where current CAR-T therapy has historically faced significant challenges due to on target, but off tumor toxicities. We look forward to advancing our pipeline of novel gamma-delta based nsCAR therapies for patients with significant unmet need.”
AACR Poster Presentation Details
Poster Title: Gamma-delta (γδ) CAR-T cells lacking the CD3ζ signaling domain enhance targeted killing of AML cells and preserve healthy tissues
Abstract Presentation Number: 5227
Session Title: Adoptive Cell Therapies 4
Session Date and Time: Tuesday, April 9, 2024, 1:30pm-5:00pm PT (4:30pm-8:00pm ET)
About INB-300
INB-300 is a non-signaling CAR (nsCAR) gamma-delta T cell platform with several preclinical product candidates, including the INB-330 program against AML targets, that combine our expertise in gamma-delta T cells and genetic engineering. These nsCAR constructs lack signaling domains in order to take advantage of the unique properties of gamma-delta T cells to differentiate between healthy and tumor tissues. IN8bio is advancing new nsCAR constructs against multiple targets to treat both solid and liquid tumors.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM). Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com.
Forward-Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the ability of IN8bio’s nsCAR platform to use the innate immune recognition of gamma-delta T cells to selectively targeting leukemia cells while preserving healthy tissues; IN8bio’s ability to use gamma delta T cells to treat a wide variety of cancers, including myeloid malignancies and solid tumors; and IN8bio’s ability to advance its pipeline of novel gamma-delta CAR-T therapies. IN8bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment, and follow-up, as well as IN8bio’s ability to meet anticipated deadlines and milestones, presented by public health crises as well as rising inflation and regulatory developments; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of IN8bio’s product candidates; the risk that IN8bio may not realize the intended benefits of its DeltEx platform; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of IN8bio’s product candidates; expectations for regulatory approvals to conduct trials or to market products; IN8bio’s reliance on third parties, including licensors and clinical research organizations; and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements are described in greater detail in the section entitled “Risk Factors” in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 9, 2023, as well as in other filings IN8bio may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and IN8bio expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances, or otherwise, except as otherwise required by law.
Company Contact:
IN8bio, Inc.
Patrick McCall
646.600.6438
info@IN8bio.com
Investors
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
FAQ
What is the focus of IN8bio's new preclinical data presented at the AACR Annual Meeting?
Where will the data be presented?
What key feature distinguishes IN8bio's nsCAR platform from current CAR-T technology?
What types of cancers is IN8bio focusing on with its gamma-delta T cell therapies?
How does IN8bio's nsCAR platform differentiate between tumor and healthy tissue?
